Background/Aims: Carnitine plays an important role in the metabolism of fatty acids. It has also been reported that the administration of anticancer drugs may lead to reductions in serum carnitine levels due to decreased activity of organic cation transporter novel 2, which plays a role in the reabsorption of carnitine in the tubules of the kidney. We therefore studied the change in carnitine levels when chemotherapy was administered repeatedly to patients with gastric cancer. Methods: Ten patients with upper gastrointestinal cancer were enrolled in this study between December 2014 and August 2015. All patients were administered chemotherapy consisting of TS-1 and cisplatin every 3 weeks: 3 received it as adjuvant therapy post resection, the remaining 7 received it as treatment for unresectable tumors. Before the start of each chemotherapy cycle, serum was collected. Results: The mean total carnitine level was 54.5 ± 13.7 μmol/L prior to commencing chemotherapy; it was 46.7 ± 13.5 and 41.4 ± 14.8 μmol/L at the second and third cycles respectively. The total carnitine level was decreased in a statistically significant manner (p = 0.0039). The serum level of total protein and cholinesterase was also decreased significantly (p = 0.0218 and p = 0.0418). Conclusion: Carnitine levels decreased during repeated chemotherapy in patients with gastric cancer, and they are associated with the nutritional status.

Keywords:
Carnitine, Chemotherapy, Ciplatin, Nutrition, Gastric cancer
1.
Wanner C, Hörl WH: Carnitine abnormalities in patients with renal insufficiency. Pathophysiological and therapeutical aspects. Nephron 1988; 50: 89–102.
2.
Fritz IB, Marquis NR: The role of acylcarnitine esters and carnitine palmityltransferase in the transport of fatty acyl groups across mitochondrial membranes. Proc Natl Acad Sci U S A 1965; 54: 1226–1233.
3.
Pons R, De Vivo DC: Primary and secondary carnitine deficiency syndrome. J Clin Neurol 1995; 10:S8–S24.
4.
Editorials: Carnitine deficiency. Lancet 1990; 335: 981–982.
5.
Costanzo M, Cannizzaro MA: Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia. World J Gastroenterol 2006; 12: 4541–4545.
6.
Busquets S, Serpe R, Toledo M, Betancourt A, Marmonti E, Orpí M, Pin F, Capdevila E, Madeddu C, López-Soriano FJ, Mantovani G, Macciò A, Argilés JM: L-carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer. Clin Nutr 201; 31: 889–895.
7.
Haschke M, Vitins T, Lüde S, Todesco L, Novakova K, Herrmann R, Krähenbühl S: Urinary excretion of carnitine as a marker of proximal tubular damage associated with platin-based antineoplastic drugs. Nephrol Dial Transplant 2010; 25: 426–433.
8.
Ikezaki T, Suzuki K, Kambara K, Inomata M, Okazawa S, Kajiura S, Miwa T, Tanabe K, Kashii T: Relationship between carnitine pharmacokinetics and fatigue in patients treated with cisplatin-containing chemotherapy. Oncol Res Treat 2017; 40: 42–45.
9.
Gomi D, Tanaka A, Fukushima T, Kobayashi T, Matsushita H, Sekiguchi N, Sakamoto A, Sasaki S, Mamiya K, Koizumi T: Dynamics of L-carnitine in plasma and urine in patients undergoing cisplatin chemotherapy. Chemotherapy 2017; 62: 225–230.
10.
Berner YN, Larchian WA, Lowry SF, Nicroa RR, Brennan MF, Shike M: Low plasma carnitine in patients on prolonged total parenteral nutrition: association with low plasma lysine. JPEN J Parenter Enteral Nutr 1990; 14: 255–258.
11.
Hassan A, Tsuda Y, Asai A, Yokohama K, Nakamura K, Sujishi T, Ohama H, Tsuchimoto Y, Fukunishi S, Abdelaal UM, Arafa UA, Hassan AT, Kassem AM, Higuchi K: Effects of oral L-carnitine on liver functions after transarterial chemoembolization in intermediate-stage HCC patients. Mediators Inflamm 2015;2015:608216.
12.
Ishikawa T, Abe S, Watanabe T, Nozawa Y, Sano T, Iwanaga A, Seki K, Honma T and Yoshida T: L-carnitine administration to cirrhotic patients with sarcopenia improves nutritional state including controlling nutritional status (CONUT) score. Int J Nutr Sci 2016; 1: 1–3.
13.
Savica V, Santoro D, Mazzaglia G, Ciolino F, Monardo P, Calvani M, Bellinghieri G, Kopple JD: L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J Ren Nutr 2005; 15: 225–230.
14.
Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, Kato M, Nakamura T, Higuchi K, Nishiguchi S, Kumada H; Long-Term Survival Study Group: Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005; 3: 705–713.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.